RECURRENT PERICARDITIS DUE TO NATALIZUMAB TREATMENT
2009; Lippincott Williams & Wilkins; Volume: 72; Issue: 18 Linguagem: Inglês
10.1212/wnl.0b013e3181a413aa
ISSN1526-632X
AutoresMikaël Cohen, Fanny Rocher, Claude Brunschwig, Christine Lebrun‐Frénay,
Tópico(s)Viral Infections and Immunology Research
ResumoNatalizumab (NTZ) (Tysabri; Biogen Idec/Elan, Cambridge, MA) is a monoclonal immunoglobulin G antibody against alpha-4-integrins, which is prescribed in France to patients with multiple sclerosis (MS) who have experienced at least one relapse during a 1-year therapy with interferon beta, an increase in the T2 lesion load and gadolinium enhancement, or in naive patients who have experienced at least two relapses and have MRI evidence of active disease.1 Adverse effects described with NTZ include most frequently intolerance-induced perfusion in up to 15% of treated patients, and hypersensitivity reactions in 4% of treated patients during or within 1 hour after perfusion, mainly during the first infusion.1,2 Development of persistent anti-NTZ antibodies is also reported in 6% of treated patients and is associated with an increased risk of developing a hypersensitivity reaction or MS relapse. To date, cardiovascular toxicity with NTZ has not been reported, except for cardiovascular manifestations associated with hypersensitivity such as tachycardia. We report a case of pericarditis, an adverse effect that has never …
Referência(s)